A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- li zhang
Sun Yat-Sen University Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Anhui Cancer Hospital
Hefei, Anhui, China
- Fujian Cancer Hospital
Fuzhou, Fujian, China
- Sun Yat-Sen Memorial Hospital，sun Yat-Sen University
Guangzhou, Guangdong, China
- Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
- Huizhou Municipal Central Hospital
Huizhou, Guangdong, China
- Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China
- the First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
- the First People'S Hospital of Yu Lin
Yulin, Guangxi, China
- the Second Affiliated Hospital of Hainan Medical University
Haikou, Hainan, China
- Zhejiang Cancer Hospital
Hangzhou, Hangzhou, China
- Hubei Cancer Hospital
Wuhan, Hubei, China
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
- Hunan Cancer Hospital
Changsha, Hunan, China
- Jiangxi Cancer Hospital
Nanchang, Jiangxi, China
- West China Hospital of Sichuan University
Chengdu, Sichuan, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Sept 2022
- Primary completion
- 30 Jan 2026
- Completion
- 30 Jan 2026
- Last update posted
- 1 Apr 2026
- Registered enrollment
- 98
- Registry id
- NCT05516914
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.